IL-1β levels were comparable to those observed in canakinumab-treated patients with monogenic auto-inflammatory diseases driven by IL-1β, such as CAPS, FMF, MKD and TRAPS. The gene discussed is IL1B; the disease is TNF receptor 1-associated periodic fever syndrome.